Megnatized Doxorubicin-loaded Erythrocytes For Targeting Tumor

Malignant tumor is a threat to human's health and life. As a common therapy, chemotherapy saves the lives of cancer patients and improves their life quality. The toxicity of drug and its non-targeted feature often lead to non-selective damage to normal tissues and organs. Sometimes it causes systemic toxicity. Therefore it's urgent to manipulate biocompatible and tumor-targeted drug carriers.Distinct from nanoparticulate drug delivery systems which are synthesized artificially, natural cell systems are more applicable and biocompatible as biological drug carriers. Cells with diverse inherent natures such as erythrocytes, stem cells and dendritic cells have been researched as novel drug delivery systems. Among these, red blood cells is prevailing due to the extensive availability, bio-compatibility, flexibility and long systemic circulation. Besides, mammal erythrocytes without nuclei make it suitable to be efficiently loaded with multiple therapeutic molecules. Applying external magnetic field (MF) to achieve tumor targeting depends on the physical force to enhance the accumulation of agents. Magnetic targeting is a simple but forceful method, comparing with other means which rely on specific binding.In this study, co-encapsulation of magnetic nanoparticles (MNPs) and doxorubicin hydrochloride into rat's erythrocytes is constructed by using a hypotonic dilution-isotonic resealing method. Nanoparticles and commercially available doxorubicin hydrochloride were evaluated for the encapsulation into red blood cells through the transient opening of membrane pores by controlled hypotonic dilution and successive isotonic resealing of cells. The morphology of the carrier erythrocytes was observed by magnetic intensity, drug loading quantity and storage stability. Using microscope, FTMS, transmission electron microscopy, scanning electron microscopy and fluorescence spectrophotometer to reveal the characterization of erythrocyte carriers. It is proved that there's no significant difference between the carrier erythrocytes and the natural ones in physical characteristics. Anticancer drug carrier erythrocytes as a tumor-targeting therapy has a certain feasibility and potential application prospects.